发布求助
文献互助 智能选刊 最新文献

Clinical Lymphoma, Myeloma & Leukemia最新文献

筛选
英文 中文
OA-27 Para-Medullary (PMD) and Extra-Medullary (EMD) Myeloma Demonstrate Increased Copy Number Aberration, Mutational Burden, Structural Variants and Genomic Complexity Compared to Marrow-Based Myeloma 与骨髓性骨髓瘤相比，OA-27 髓旁骨髓瘤（PMD）和髓外骨髓瘤（EMD）表现出更高的拷贝数畸变、突变负荷、结构变异和基因组复杂性
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01868-8
{"title":"OA-27 Para-Medullary (PMD) and Extra-Medullary (EMD) Myeloma Demonstrate Increased Copy Number Aberration, Mutational Burden, Structural Variants and Genomic Complexity Compared to Marrow-Based Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01868-8","DOIUrl":"10.1016/S2152-2650(24)01868-8","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-08 Safety and Preliminary Efficacy of BMS-986393, a GPRC5D CAR T Cell Therapy, in Patients (pts) With Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Results From a Phase 1 Study OA-08 GPRC5D CAR T细胞疗法BMS-986393在复发/难治性（RR）多发性骨髓瘤（MM）患者（pts）中的安全性和初步疗效：1期研究结果
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01849-4
{"title":"OA-08 Safety and Preliminary Efficacy of BMS-986393, a GPRC5D CAR T Cell Therapy, in Patients (pts) With Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Results From a Phase 1 Study","authors":"","doi":"10.1016/S2152-2650(24)01849-4","DOIUrl":"10.1016/S2152-2650(24)01849-4","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Copyright Page 版权页
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01840-8
{"title":"Copyright Page","authors":"","doi":"10.1016/S2152-2650(24)01840-8","DOIUrl":"10.1016/S2152-2650(24)01840-8","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-013 CERVINO: A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared With Standard Available Therapies in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) P-013 CERVINO：ABBV-383与现有标准疗法在复发性或难治性多发性骨髓瘤（RRMM）患者中的3期、多中心、随机、开放标签研究
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01916-5
{"title":"P-013 CERVINO: A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared With Standard Available Therapies in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)","authors":"","doi":"10.1016/S2152-2650(24)01916-5","DOIUrl":"10.1016/S2152-2650(24)01916-5","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-62 Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, Dexamethasone vs Pomalidomide Plus Bortezomib, Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma OA-62 贝兰他单抗马福多汀、泊马度胺、地塞米松与泊马度胺加硼替佐米、地塞米松（PVd）治疗复发性/难治性多发性骨髓瘤的随机3期DREAMM-8研究结果
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01903-7
{"title":"OA-62 Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, Dexamethasone vs Pomalidomide Plus Bortezomib, Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01903-7","DOIUrl":"10.1016/S2152-2650(24)01903-7","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-032 Real-World Analysis of Teclistamab Treatment for Relapsed Refractory Multiple Myeloma in Two Belgian University Hospitals P-032 比利时两所大学医院对替卡单抗治疗复发难治多发性骨髓瘤的真实世界分析
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01935-9
{"title":"P-032 Real-World Analysis of Teclistamab Treatment for Relapsed Refractory Multiple Myeloma in Two Belgian University Hospitals","authors":"","doi":"10.1016/S2152-2650(24)01935-9","DOIUrl":"10.1016/S2152-2650(24)01935-9","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-49 Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ) 伊沙妥昔单抗、硼替佐米、来那度胺和地塞米松（Isa-VRd）与VRd治疗新诊断多发性骨髓瘤（IMROZ）移植不合格患者的OA-49 3期研究结果
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01890-1
{"title":"OA-49 Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)","authors":"","doi":"10.1016/S2152-2650(24)01890-1","DOIUrl":"10.1016/S2152-2650(24)01890-1","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-06 Impact of Clonal Hematopoiesis on Clinical Outcomes to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma OA-06 克隆造血对多发性骨髓瘤 BCMA 导向 CAR T 细胞疗法临床疗效的影响
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01847-0
{"title":"OA-06 Impact of Clonal Hematopoiesis on Clinical Outcomes to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01847-0","DOIUrl":"10.1016/S2152-2650(24)01847-0","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-005 Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma P-005 桥接疗法的有效性与接受CAR-T疗法后的疗效改善相对应：复发、来那度胺难治性多发性骨髓瘤患者的3期CARTITUDE-4研究
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01908-6
{"title":"P-005 Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01908-6","DOIUrl":"10.1016/S2152-2650(24)01908-6","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-024 Phase Ib Study Investigating the Safety, Pharmacokinetics, and Efficacy of Subcutaneous Administration of ABBV-383 in Patients With Relapsed/Refractory Multiple Myeloma P-024 Ib 期研究：调查皮下注射 ABBV-383 对复发性/难治性多发性骨髓瘤患者的安全性、药代动力学和疗效
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01927-X
{"title":"P-024 Phase Ib Study Investigating the Safety, Pharmacokinetics, and Efficacy of Subcutaneous Administration of ABBV-383 in Patients With Relapsed/Refractory Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01927-X","DOIUrl":"10.1016/S2152-2650(24)01927-X","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信